8 new oncology trials approved in Europe
 |
Oncology Hero |
8 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe.
Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial.
| Sponsor: Consorci Mar Parc De Salut De Barcelona | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA phase 2 study to assess efficacy of induction Enfortumab Vedotin plus Pembrolizumab using a response-adapted approach to spare the bladder: FIDELIO
| Sponsor: Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestctDNA-guided Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Urothelial Carcinoma. The FUTURE Study
| Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase: 4 |
Interested in offering this trial to suitable patients?
Register Investigator InterestHepatic arterial infusion versus intravenous oxaliplatin in a safety, feasibility and pharmacokinetic study of liver-dominant malignancies – ARTEMIS OXYS-I trial
| Sponsor: Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Phase: 1 |
Interested in offering this trial to suitable patients?
Register Investigator InterestLIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors
| Sponsor: Merck Sharp & Dohme LLC | Phase: 2 |
Not accepting new sites
A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (TE NDMM) (DURGA-6)
| Sponsor: AstraZeneca AB | Phase: 3 |
Not accepting new sites
A Phase Ib/II, open-label, safety and tolerability trial of obrixtamig in combination with ZL-1310 in patients with poorly differentiated NEC
| Sponsor: Boehringer Ingelheim International GmbH | Phase: 1, 2 |
Not accepting new sites
First-in-human study of ATX-898 as monotherapy and in combination with other anti-neoplastic agents, in participants with advanced solid tumors
| Sponsor: Antares Therapeutics Inc. | Phase: 1, 2 |
Not accepting new sites
Oncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
Oncology Hero 8 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. RINGQUEST: Exploring Understudied Genitourinary Tumors with Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study. Sponsor: Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest [18F] MC225 PET...
Oncology Hero 15 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Use of the Checkpoint inhibitor DOstarlimab in the endOmetrial cancer fertility-Sparing trEatment: CHOOSE study Sponsor: UZ Leuven Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest Antibody-based PET imaging and treatment response in breast cancer treated with an...
Oncology Hero 6 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL) Sponsor: Oslo Universitetssykehus HF Phase: Not specified Interested in offering this trial to suitable patients? Register Investigator Interest A Phase 3 Randomized Study...